Von Hippel-Lindau (VHL) Syndrome
An inherited disorder, Von Hippel-Lindau (VHL) syndrome is characterized by the formation of tumors and fluid-filled sacs (cysts) in up to ten different parts of the body including the brain, spine, eyes, kidneys, pancreas, adrenal glands, inner ears, reproductive tract, liver, and lungs.
The disease has no cure; however, timely diagnosis can significantly improve the course of the disease. If left undetected or untreated, it can result in permanent brain damage and even death.
However, a lot of research is ongoing, and several pharma players are working to find a standard treatment for VHL syndrome.
Know about the ongoing R&D, and a lot more by filling up the form towards your right. Know about the disease, underlying causes, treatment options, and unmet needs in the market.
Gain insights into the VHL syndrome market and recent happenings, key collaborations, and breakthroughs in the domain.
Subscribe to DelveInsight’s mailing list and never miss an update on Life Science vertical. Stay tuned for more.
Know more about What's covered:
- Indication overview
- Epidemiological trends
- Treatment approaches
- Key Companies
- Pipeline drugs
- Collaborations and deals in the domain
- R&D in the field
- Top conferences
- Support from International organizations
